These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 28928054)
1. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats. Kanda J; Izumo N; Kobayashi Y; Onodera K; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H J Pharmacol Sci; 2017 Sep; 135(1):22-28. PubMed ID: 28928054 [TBL] [Abstract][Full Text] [Related]
2. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats. Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085 [TBL] [Abstract][Full Text] [Related]
3. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917 [TBL] [Abstract][Full Text] [Related]
4. The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. Koufany M; Chappard D; Netter P; Bastien C; Weryha G; Jouzeau JY; Moulin D Arthritis Rheum; 2013 Dec; 65(12):3084-95. PubMed ID: 23982996 [TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331 [TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats. Smith SY; Samadfam R; Chouinard L; Awori M; Bénardeau A; Bauss F; Guldberg RE; Sebokova E; Wright MB J Bone Miner Metab; 2015 Nov; 33(6):625-41. PubMed ID: 25534548 [TBL] [Abstract][Full Text] [Related]
7. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis. Koufany M; Jouzeau JY; Moulin D Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921 [TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294 [TBL] [Abstract][Full Text] [Related]
9. Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats. Kanda J; Izumo N; Furukawa M; Shimakura T; Yamamoto N; E Takahashi H; Asakura T; Wakabayashi H Biomed Res; 2018; 39(3):131-139. PubMed ID: 29899188 [TBL] [Abstract][Full Text] [Related]
10. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684 [TBL] [Abstract][Full Text] [Related]
11. Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats. Eom YS; Gwon AR; Kwak KM; Kim JY; Yu SH; Lee S; Kim YS; Park IB; Kim KW; Lee K; Kim BJ PLoS One; 2016; 11(12):e0168569. PubMed ID: 27997588 [TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588 [TBL] [Abstract][Full Text] [Related]
13. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Lecka-Czernik B Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203 [TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Okazaki R; Toriumi M; Fukumoto S; Miyamoto M; Fujita T; Tanaka K; Takeuchi Y Endocrinology; 1999 Nov; 140(11):5060-5. PubMed ID: 10537132 [TBL] [Abstract][Full Text] [Related]
15. The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus. Mori H; Okada Y; Tanaka Y Intern Med; 2017; 56(11):1301-1306. PubMed ID: 28566590 [TBL] [Abstract][Full Text] [Related]
16. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. Harada S; Mizoguchi T; Kobayashi Y; Nakamichi Y; Takeda S; Sakai S; Takahashi F; Saito H; Yasuda H; Udagawa N; Suda T; Takahashi N J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469 [TBL] [Abstract][Full Text] [Related]
17. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Beck GR; Khazai NB; Bouloux GF; Camalier CE; Lin Y; Garneys LM; Siqueira J; Peng L; Pasquel F; Umpierrez D; Smiley D; Umpierrez GE Transl Res; 2013 Mar; 161(3):145-55. PubMed ID: 23022285 [TBL] [Abstract][Full Text] [Related]